This inventor holds 51 USPTO granted patents and 11 published patent applications, plus 11 CIPO patents and 15 EPO patents, primarily in Oligonucleotide Delivery (CPC class C12N). Top assignees: Alnylam Pharmaceuticals, Inc., Arrowhead Madison, Inc., Axolabs Gmbh. Active years: 2008-2025.
Inventors with similar research interests:
Location History:
- Alenkunstadt, DE (2011)
- Bayreuth, DE (2009 - 2015)
- Cambridge, MA (US) (2012 - 2015)
- Altenkunstadt, DE (2008 - 2017)
- Kulmbach, DE (2010 - 2023)
Company Filing History:
30 out of 465 
6 out of 19 
5 out of 7 
Years Active: 2008-2025
Areas of Expertise:
As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide you with the requested article about inventor Philipp Hadwiger. Here is the structured article based on the given data:
Title: The Innovations of Philipp Hadwiger - Pioneering Defined Multi-Conjugate Oligonucleotides
Introduction:
Philipp Hadwiger, a male inventor hailing from Altenkunstadt, Germany, is a renowned figure in the field of molecular biology and nucleotide chemistry. With an impressive portfolio of 50 patents to his name, Hadwiger has significantly advanced the development of defined multi-conjugate oligonucleotides, revolutionizing the fields of gene expression modulation, biological research, and medical treatment.
Latest Patents:
Hadwiger's groundbreaking work revolves around defined multi-conjugate oligonucleotides, which can be tailored to specific sizes and compositions. These oligonucleotides exhibit exceptional properties, such as enhanced intracellular delivery and multi-gene silencing effects. By employing novel synthetic intermediates and methods, Hadwiger has paved the way for the synthesis and application of these oligonucleotides in diverse areas, including gene expression regulation, medical interventions, and cellular phenotype manipulation.
Career Highlights:
During his illustrious career, Philipp Hadwiger has made significant contributions to companies at the forefront of biotechnological innovation. He has lent his expertise to Alnylam Pharmaceuticals, Inc. and Arrowhead Madison, Inc., where he has played a key role in driving research and development initiatives aimed at harnessing the potential of defined multi-conjugate oligonucleotides for therapeutic and research purposes.
Collaborations:
Throughout his career, Hadwiger has collaborated closely with esteemed colleagues such as Hans-Peter Vornlocher and Ingo Roehl. Together, they have synergized their expertise to advance the field of nucleotide chemistry and biotechnology, leading to the successful realization of innovative solutions and novel applications in molecular biology.
Conclusion:
In conclusion, Philipp Hadwiger stands as a trailblazer in the realm of molecular biology and oligonucleotide synthesis, with his pioneering work on defined multi-conjugate oligonucleotides reshaping the landscape of gene modulation and biomedical research. His relentless pursuit of innovation and collaboration with industry leaders have not only propelled scientific advancements but also have the potential to drive transformative changes in medicine and biotechnology.